Biogen rose 4.3% during the afternoon session to $303.86 per share. As reported by Barrons: "Big Alzheimer's News for Biogen Has Landed. The Company Didn't Get a Mention. ..." You can read more about it here. For those of you thinking about investing in the stock, here is a brief look at the company's fundamentals.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) ratio of 4.07. In contrast, Biogen has a trailing 12 month P/E ratio of 15.8 and a P/B ratio of 4.3.
At today's price of $303.86 per share, Biogen is 2.85% away from its target price of $295.44, and on average, analysts give the stock a rating of buy. 1.9% of the company's shares are linked to short positions, and 87.3% of the shares are owned by institutional investors.